Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ART5803 Following IVIG in Healthy Participants
NCT06753955Phase 1Completed
- Sponsor
- Arialys Therapeutics
- Start
- Feb 2025
- Primary completion
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ART5803 in anti-N-methyl D-aspartate receptor encephalitis, sponsored by Arialys Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events at 13 Weeks, Clinically significant changes in physical and neurological examination findings at 13 Weeks and 8 more. Started Feb 2025; status: completed.
02
Drugs
ART5803
03
Conditions
anti-N-methyl D-aspartate receptor encephalitis
Beyond the preview
Go deeper on NCT06753955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06753955.